Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

NCT06938867 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

E Coli Infections
Allogenic Transplant Patients

Interventions

BIOLOGICAL: SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli
OTHER: Placebo 10 mL

Sponsor

SNIPR Biome Aps.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]